UroGen Pharma Ltd. — Director's Dealing 2020

Mar 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-03-04

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-04	Ordinary Shares	M	1042	—	Acquired	17918	Direct
2020-03-04	Ordinary Shares	F	345	$29.50	Disposed	17573	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-04	Restricted Stock Units	$	M	1042	Disposed		Ordinary Shares (1042)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The transaction reported herein was matchable under Section 16(b) of the Securities and Exchange Act of 1934, to the extent of 345 shares, with the reporting person's purchase of 1,960 ordinary shares of the Issuer at a price of $28.17 per share on November 19, 2019. The reporting person has paid to the Issuer $458.85, representing the full amount of the profit realized in connection with the short-swing transaction.

F4: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of three years.